Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?

Sarcopenia, as defined by the European Working Group on Sarcopenia (EWGSOP) in Older People is “a progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality”. The first EWGSOP an...

Full description

Saved in:
Bibliographic Details
Main Author: Siti Setiati
Format: Article
Language:English
Published: Interna Publishing 2019-08-01
Series:Acta Medica Indonesiana
Subjects:
Online Access:https://www.actamedindones.org/index.php/ijim/article/view/1223
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849467840652902400
author Siti Setiati
author_facet Siti Setiati
author_sort Siti Setiati
collection DOAJ
description Sarcopenia, as defined by the European Working Group on Sarcopenia (EWGSOP) in Older People is “a progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality”. The first EWGSOP and Asian Working Group for Sarcopenia used muscle mass to define sarcopenia, which is diagnosed by using Dual-energy X-Ray absorptiometry (DXA). However, the cut-off from several countries in Asian showed different cut-off value for different age groups and BMI. In addition, not all hospitals and countries can afford DXA to be used as daily diagnostic routine for sarcopenia. In 2018, EWGSOP made a revision regarding sarcopenia, as well as the diagnostic test and cut-off value (EWGSOP2). EWGSOP2 recommends using self-questionnaire, known as SARC-F as sarcopenia screening, especially in community-dwelling elderly. SARC-F consisted of 5 questions regarding patient’s perception of his or her limitations in strength, walking ability, rising from a chair, stair climbing and experiences with falls. This is more feasible to be done in countries without advanced muscle mass measurement tools. Several parameters in sarcopenia are muscle strength, muscle quantity, and physical performance. In muscle strength, measuring grip strength can be done as predictor for patients’ outcomes, such as hospitalization and quality of life. For muscle quantity, the gold standards are Magnetic resonance imaging (MRI) and computed tomography (CT). However, since both are expensive, and the cut-off points have not been defined yet, DXA and Bioelectrical impedance analysis (BIA) can be a substitute. Current evidence showed that DXA still does not give consistent results and not yet portable for the use in the community. On the other hand, BIA measure muscle mass using the whole-body electrical conductivity and less expensive than the other tools, thus can be used in the community setting. However, there is no specific cut-off for BIA especially in elderly. For physical performance, several tests can be done, such as gait speed and Timed-Up and Go test (TUG).
format Article
id doaj-art-f4e3daaccbaa46bd9b8b59fc81558110
institution Kabale University
issn 0125-9326
2338-2732
language English
publishDate 2019-08-01
publisher Interna Publishing
record_format Article
series Acta Medica Indonesiana
spelling doaj-art-f4e3daaccbaa46bd9b8b59fc815581102025-08-20T03:26:03ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322019-08-01512Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?Siti Setiati0Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Clinical Epidemiology and Evidence Based Medicine Unit, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.Sarcopenia, as defined by the European Working Group on Sarcopenia (EWGSOP) in Older People is “a progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality”. The first EWGSOP and Asian Working Group for Sarcopenia used muscle mass to define sarcopenia, which is diagnosed by using Dual-energy X-Ray absorptiometry (DXA). However, the cut-off from several countries in Asian showed different cut-off value for different age groups and BMI. In addition, not all hospitals and countries can afford DXA to be used as daily diagnostic routine for sarcopenia. In 2018, EWGSOP made a revision regarding sarcopenia, as well as the diagnostic test and cut-off value (EWGSOP2). EWGSOP2 recommends using self-questionnaire, known as SARC-F as sarcopenia screening, especially in community-dwelling elderly. SARC-F consisted of 5 questions regarding patient’s perception of his or her limitations in strength, walking ability, rising from a chair, stair climbing and experiences with falls. This is more feasible to be done in countries without advanced muscle mass measurement tools. Several parameters in sarcopenia are muscle strength, muscle quantity, and physical performance. In muscle strength, measuring grip strength can be done as predictor for patients’ outcomes, such as hospitalization and quality of life. For muscle quantity, the gold standards are Magnetic resonance imaging (MRI) and computed tomography (CT). However, since both are expensive, and the cut-off points have not been defined yet, DXA and Bioelectrical impedance analysis (BIA) can be a substitute. Current evidence showed that DXA still does not give consistent results and not yet portable for the use in the community. On the other hand, BIA measure muscle mass using the whole-body electrical conductivity and less expensive than the other tools, thus can be used in the community setting. However, there is no specific cut-off for BIA especially in elderly. For physical performance, several tests can be done, such as gait speed and Timed-Up and Go test (TUG).https://www.actamedindones.org/index.php/ijim/article/view/1223sarcopeniathe European Working Group on Sarcopenia (EWGSOP)SARC-F
spellingShingle Siti Setiati
Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
Acta Medica Indonesiana
sarcopenia
the European Working Group on Sarcopenia (EWGSOP)
SARC-F
title Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
title_full Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
title_fullStr Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
title_full_unstemmed Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
title_short Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
title_sort diagnostic tools for sarcopenia can we get less expensive and accurate methods
topic sarcopenia
the European Working Group on Sarcopenia (EWGSOP)
SARC-F
url https://www.actamedindones.org/index.php/ijim/article/view/1223
work_keys_str_mv AT sitisetiati diagnostictoolsforsarcopeniacanwegetlessexpensiveandaccuratemethods